Caribou Biosciences Inc’s recent filing unveils that its President and CEO Haurwitz Rachel E. acquired Company’s shares for reported $20400.0 on Mar 14 ’25. In the deal valued at $1.02 per share,20,000 shares were bought. As a result of this transaction, Haurwitz Rachel E. now holds 3,369,395 shares worth roughly $3.54 million.
Then, MCCLUNG BARBARA G sold 3,564 shares, generating $4,811 in total proceeds. Upon selling the shares at $1.35, the Chief Legal Officer now owns 443,502 shares.
Before that, Khan Ruhi Ahmad sold 3,564 shares. Caribou Biosciences Inc shares valued at $4,811 were divested by the Chief Business Officer at a price of $1.35 per share. As a result of the transaction, Khan Ruhi Ahmad now holds 66,936 shares, worth roughly $70282.8.
Evercore ISI downgraded its Caribou Biosciences Inc [CRBU] rating to an In-line from a an Outperform in a research note published on June 03, 2024; the price target was decreased to $3 from $13. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in early November with a ‘”a Neutral”‘ rating. Evercore ISI began covering CRBU with “an Outperform” recommendation on October 31, 2023. Truist started covering the stock on July 11, 2023. It rated CRBU as “a Buy”.
Price Performance Review of CRBU
On Monday, Caribou Biosciences Inc [NASDAQ:CRBU] saw its stock jump 11.89% to $1.05. Over the last five days, the stock has gained 28.35%. Caribou Biosciences Inc shares have fallen nearly -33.96% since the year began. Nevertheless, the stocks have fallen -71.15% over the past one year.
How much short interest is there in Caribou Biosciences Inc?
A steep rise in short interest was recorded in Caribou Biosciences Inc stocks on 2025-04-30, dropping by -2.25 million shares to a total of 7.63 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 9.89 million shares. There was a decline of -29.54%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 18, 2022 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $22 price target.
